KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Receivables: 2018-2025

Historic Change in Receivables for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $1.0 billion.

  • Moderna's Change in Receivables fell 27.69% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$503.0 million, marking a year-over-year decrease of 66.56%. This contributed to the annual value of -$534.0 million for FY2024, which is 8.32% down from last year.
  • As of Q3 2025, Moderna's Change in Receivables stood at $1.0 billion, which was up 3,476.67% from -$30.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Change in Receivables peaked at $1.8 billion during Q1 2021, and registered a low of -$1.3 billion during Q4 2022.
  • Over the past 3 years, Moderna's median Change in Receivables value was -$272.0 million (recorded in 2023), while the average stood at -$29.5 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 90,850.00% in 2021, then crashed by 27,100.00% in 2023.
  • Quarterly analysis of 5 years shows Moderna's Change in Receivables stood at $33.0 million in 2021, then tumbled by 4,069.70% to -$1.3 billion in 2022, then increased by 25.65% to -$974.0 million in 2023, then decreased by 23.82% to -$1.2 billion in 2024, then decreased by 27.69% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, -$30.0 million for Q2 2025, and -$280.0 million during Q1 2025.